FDA IND clearance for a second indication (FSHD) with no approved therapies is a significant pipeline expansion. The non-dilutive funding extends cash runway without shareholder dilution. Watch for Phase 2 FSHD trial initiation in Q4 2026 and any interim DMD data readouts that could further derisk the platform.
Price Chart
Executive Summary
Satellos announced FDA clearance of its IND application for forazapadin in FSHD, a second indication with no approved therapies, and secured up to US$5 million in non-dilutive financing from the FSHD Canada Foundation. A Phase 2 FSHD study is expected to begin in Q4 2026. This expands the pipeline beyond DMD and provides capital without dilution.
Key Facts
- FDA cleared IND for forazapadin in FSHD
- Phase 2 FSHD study expected to start Q4 2026
- FSHD Canada Foundation to provide up to US$5 million in non-dilutive milestone payments over five quarters
- Forazapadin is also in Phase 2 for DMD (BASECAMP and TRAILHEAD trials)
- FSHD affects an estimated 800,000 individuals worldwide with no approved disease-modifying therapies
- IND clearance includes 60 mg and 120 mg dose levels
Financial Impact
Up to US$5 million in non-dilutive financing from FSHD Canada Foundation; no dilution to existing shareholders
Risk Factors
- Phase 2 FSHD trial may fail to show efficacy or safety
- Preliminary DMD data may not replicate in larger studies
- Company remains pre-revenue with ongoing cash burn; future financing may still be needed
- FSHD Canada Foundation funding is milestone-based and may not be fully received
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006202 |
| Document: f6k_092326.htm | 0001171843-26-006202 |
| Document: 0001171843-26-006202-index-headers.html | 0001171843-26-006202 |
| Document: 0001171843-26-006202-index.html | 0001171843-26-006202 |
| Document: 0001171843-26-006202.txt | 0001171843-26-006202 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers